CALGARY, Alberta, March 02, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc.
(“XORTX” or the “Company”) (CSE: XRX;
OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative
therapies to treat progressive kidney disease, is pleased to announce that
4,286,438 warrants that were issued in connection with the February 2020
private placement and expired February 28, 2021 have been exercised for
aggregate proceeds of $1,037,524.
› Read more